Ajanta Pharma Limited — Board Meeting, 30-01-2025: Outcome of Board Meeting

The Board has approved the unaudited financial results for the quarter and nine months ended 31 December 2024. Key highlights include a 4% rise in revenue, totaling ₹1,146 Cr, and an 11% increase in profit after tax at ₹233 Cr. For the nine months, revenue grew 10% to ₹3,478 Cr, with a 13% rise in profit after tax, reaching ₹695 Cr. The company continues to experience strong performance across its branded generic segments, with notable growth in therapeutic areas like dermatology and pain management.